Masters Speciality Pharma

Name

Masters Speciality Pharma

Legal name

Masters Pharmaceuticals Limited

Website

https://mastersglobal.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Specialty Pharmaceutical Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

akta.pro secondary industries

Specialty Pharmaceutical Distributors (HLAIAJAB), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Pharmaceutical distribution services
• Specialty medicines supply
• Rare disease therapies
• Orphan drug distribution
• Regulatory affairs services

Headquarters

HQ city

Elstree

HQ country

United Kingdom

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Distribution: Masters generates revenue through exclusive distribution agreements with pharmaceutical companies. They manage complete supply chain from storage and fulfilment to worldwide distribution, ensuring reliability and continuity of supply for partner products in emerging markets.
2. Sales & Marketing Services: Revenue from sales and marketing services including national key account management, KOL advocacy, brand awareness initiatives, and demand generation activities for pharmaceutical products in specified markets.
3. Licensing & Regulatory Services: Revenue generated from licensing and regulatory services including product registration, dossier preparation and submission, marketing authorisation holding, and post-registration lifecycle management.
4. Marketing Authorisation Holding: Full MA holding in specified markets with responsibility for regulatory compliance and oversight, including pharmacovigilance and product lifecycle management.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Masters Speciality Pharma is a pharmaceutical distribution and supply chain company that supplies specialty medicines to hospitals, clinics, government institutions, and pharmaceutical companies across emerging markets including the UK, GCC, Brazil, and Central America. The company provides exclusive distribution, sales & marketing, licensing & regulatory, and local marketing authorisation (MA) holding services for specialty products targeting rare diseases, sickle cell disease, oncology, and haematology. Its portfolio includes Siklos® (hydroxycarbamide), Daptomycin, Clarithromycin, Sugammadex, Bortezomib, and Mercaptopurine, distributed through temperature-controlled GxP-compliant logistics.

Product overview

Masters Speciality Pharma is a global pharmaceutical distribution company offering a portfolio of specialty medicines alongside integrated commercial services. The product portfolio includes Siklos® (hydroxycarbamide) for sickle cell disease, antibiotics (Daptomycin, Clarithromycin), Sugammadex for anaesthesia, and oncology treatments (Bortezomib, Mercaptopurine). These are distributed through exclusive distribution, sales & marketing, licensing & regulatory, and local marketing authorisation holding services across the UK, GCC, Brazil, and Central America markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Siklos® 100mg and Siklos® 1000mg tablets (Hydroxycarbamide) Hydroxycarbamide medication used for the prevention of vaso-occlusive crisis in patients aged two years and older with Sickle Cell Disease. Available in 100mg and 1000mg scored tablets for precise dosing. Distributed exclusively by Masters in the UK and parts of GCC under partnership with Theravia.
• Daptomycin 500mg vial Bacterial antibiotic for the treatment of gram-positive infections. Distributed in GCC markets where Masters holds the local marketing authorisation in partnership with Anfarm Hellas S.A.
• Clarithromycin 500mg vial A macrolide antibiotic used to treat various bacterial infections. Distributed in GCC markets under local marketing authorisation held by Masters in partnership with Anfarm Hellas S.A.
• Sugammadex 100mg/ml vial A reversal agent for neuromuscular blockade induced by anaesthesia. Distributed in GCC markets under local marketing authorisation held by Masters in partnership with Anfarm Hellas S.A.
• Bortezomib 3.5mg vial A proteasome inhibitor for the treatment of multiple myeloma and mantle cell lymphoma. Distributed in Central American markets under local marketing authorisation held by Masters in partnership with Synchrony Pharma.
• Mercaptopurine 50mg tablets An antimetabolite for the treatment of acute leukaemia. Distributed in Central American markets under local marketing authorisation held by Masters in partnership with Geiser Pharma.
• Exclusive Distribution Services Complete supply chain management from storage and fulfilment to worldwide distribution, ensuring reliability and continuity of supply. Includes detailed market insight, disease mapping, temperature-controlled logistics, and GxP-compliant operations for partner pharmaceutical companies.
• Sales & Marketing Services Sales and marketing strategy development aligned with business objectives and local market realities, including detailed target and KOL mapping, advocacy programs, brand awareness initiatives, demand generation activities, and national key account management for pharmaceutical partners.
• Licensing and Regulatory Services Expertise in navigating local regulatory landscapes including product registration, dossier preparation and submission, with ongoing post-registration and life-cycle management across UK, GCC, Brazil, and Central American markets.
• Marketing Authorisation Holding Services Full Marketing Authorisation (MA) holding in specified markets with responsibility for regulatory compliance, pharmacovigilance, and product life-cycle management. Includes successful MA transfers such as Desferal from Novartis to Masters in Brazil.

Quantifiable outcome

• Serving over 75 countries worldwide with life-saving medicines
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core and secondary.

• TheraviacoreStrategic or Co-development PartnerExclusive partnership for distribution of Siklos (hydroxycarbamide) for treatment of Sickle Cell Disease across UK and expansion into Saudi Arabia. Masters serves as exclusive distribution partner for Theravia with focused commercial strategy, national key account management, and KOL advocacy to improve patient access to Siklos in UK NHS hospitals.
• Mitem PharmacoreChannel Partner/ Reseller/ DistributorStrategic partnership for commercialization of Desferal in Brazil. Mitem Pharma collaboration enabled successful transfer of Marketing Authorisation from Novartis to Masters and implementation of locally tailored commercial strategy with dedicated haematology sales force.
• AddmedicacoreChannel Partner/ Reseller/ DistributorOriginal developer of Siklos. Masters obtained exclusive license and distribution agreement for Siklos in Brazil, responsible for regulatory filing with Brazilian Health authorities and exclusive distribution in the country.
• Anfarm Hellas S.A.secondaryChannel Partner/ Reseller/ DistributorPartnership for multiple products in GCC markets including Daptomycin 500mg, Clarithromycin 500mg, and Sugammadex 100mg/ml. Masters holds local marketing authorisation holder status for these products in GCC region.
• Synchrony PharmasecondaryChannel Partner/ Reseller/ DistributorPartnership for Bortezomib 3.5mg distribution in Central America. Masters holds local marketing authorisation holder status for this product in the Central American market.
• Geiser PharmasecondaryChannel Partner/ Reseller/ DistributorPartnership for Mercaptopurine 50mg tablets distribution in Central America for treatment of acute leukaemia. Masters holds local marketing authorisation holder status.
• NovartiscoreStrategic or Co-development PartnerMajor pharmaceutical partner for sourcing and supply of medicines. Novartis transferred Desferal marketing authorisation to Masters through partnership with Mitem Pharma. Masters has over 30 years track record of sourcing medicines from UK, Europe and US including Novartis products for oncology, haematology, pain management and rare diseases.
• AlexionsecondaryChannel Partner/ Reseller/ DistributorLife science partner for specialty medicines. Masters partners with innovative life-science companies including Alexion to provide access to specialty medicines for unmet needs including rare disease treatments.
• AmgensecondaryChannel Partner/ Reseller/ DistributorLife science partner for specialty medicines. Masters partners with Amgen to provide access to specialty medicines for emerging markets and rare disease treatments.
• European Contract Manufacturing Organisations (CMOs)secondaryTechnology or IntegrationStrategic partnerships with European CMOs to support development, manufacturing, and supply of high-quality pharmaceutical products. These partnerships allow bringing specialised products to market efficiently while maintaining stringent quality and regulatory standards.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Durbin plc: UK-based pharmaceutical distributor specializing in supply of unlicensed, named-patient, and specialty medicines to hospitals, clinicians, and wholesalers worldwide. Closely comparable to Masters in scale, UK origin, and focus on hard-to-source specialty pharmaceuticals for emerging and regulated markets.
• Clinigen Group: UK-headquartered specialty pharma services company providing access to unlicensed, named-patient, and specialty medicines globally. Highly comparable to Masters in business model, target customer base (pharma manufacturers seeking complex market access), and integrated service offering spanning distribution, regulatory, and commercial services.
• Abacus Medicine: Denmark-headquartered pharmaceutical company distributing parallel-imported, unlicensed, and specialty medicines across European and international markets. Comparable to Masters in its focus on access to medicines not readily available through standard distribution channels and its specialist hospital customer base.

Broad incumbents

• McKesson Corporation: One of the world's largest pharmaceutical distributors and healthcare services companies, with deep specialty pharma and rare disease capabilities through US Oncology and McKesson Specialty Health. Comparable to Masters in distributing specialty and rare disease products, but at vastly greater scale and breadth of geography.
• Phoenix Group: One of the largest pharmaceutical distribution companies in Europe, operating wholesale and pre-wholesale services across 27+ countries. Comparable as a pharma distributor serving European and adjacent emerging markets, but with vastly greater scale and a generalized rather than specialty focus.
• Cencora (formerly AmerisourceBergen): Global pharmaceutical solutions company distributing specialty and traditional pharmaceuticals, including through its World Courier specialty logistics business. Comparable to Masters in specialty distribution capabilities but operates at massive global scale across all therapeutic areas.
• Alliance Healthcare: Walgreens Boots Alliance subsidiary and one of Europe's largest pharmaceutical wholesalers, distributing medicines to pharmacies, hospitals, and clinics across multiple countries. Comparable to Masters as a pharma distribution operator but with significantly greater scale and a broader portfolio rather than Masters' specialty/rare-disease focus.

Emerging players

• Consilient Health: European specialty pharmaceutical company focused on licensing, marketing, and distribution of branded and generic medicines in therapeutic areas including women's health and oncology. Comparable to Masters in its specialty pharma licensing and distribution model across multiple European markets.
• Eumedica Pharmaceuticals: European specialty pharmaceutical company focused on licensing, marketing, and distributing hospital specialty medicines including anti-infectives and oncology products. Comparable to Masters in its specialty pharma distribution model targeting hospitals and in its licensing-led approach.
• Genmedica Therapeutics: European specialty pharma company operating across Southern and Eastern Europe and emerging markets, focused on rare diseases, oncology, and specialty therapeutics. Comparable to Masters in geographic focus on complex emerging European and adjacent markets and in rare/specialty pharma positioning.

Market position

Strengths4 records

Weaknesses2 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/masters-speciality-pharma
• Xx.com/masters_sp

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Masters Speciality Pharma